[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retina-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retina-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645379","cirrus-2023-1-clinical-clin-assessment-of-pathfinder-10-on-the-cirrus-6000-and-the-cirrus-5000-100645379",false,"NCT07680244","(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000","Inclusion Criteria:\n\n1. Able and willing to make the required study visits.\n2. Able and willing to give written informed consent and follow study instructions.\n3. Able and willing to complete ophthalmic imaging.\n4. Adults 18 years of age or older.\n\nThe subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area):\n\nGroup A\n\n1\\. Subjects with absence of macular abnormalities Group B\n\n1. Subjects with Disruption of the vitreoretinal interface (VRI)\n2. Subjects with Intraretinal hyporeflective space (IRHS)\n3. Subjects with Subretinal hyporeflective space (SRHS)\n4. Subjects with IS\u002FOS (Ellipsoid Zone) disruption\n5. Subjects with Retinal Pigment Epithelium (RPE) elevation\n6. Subjects with Retinal Pigment Epithelium (RPE) atrophy\n7. Other abnormalities\n\nExclusion Criteria:\n\n1. Inability to undergo the required tests.\n2. Unable to give consent or follow study instructions.\n3. Inability to fixate that precludes obtaining acceptable macula scans in the study eye.\n4. Visudyne (verteporfin) injection within the last 48 hours in the study eye.\n5. Pilocarpine or Vuity use within the last 24 hours in the study eye.\n6. Dense media opacity precluding adequate visualization of the retina in the study eye.\n7. Vitreous floaters that preclude obtaining acceptable scans in the study eye.",true,"ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.",[26,27,28,29,30,31,32,33,34,35],"Epiretinal Membrane","Dry Age Related Macular Degeneration","Macular Abnormalities","Retina Disease","Vitreoretinal Abnormality","Intraretinal Hyporeflective Space","Subretinal Hyporeflective Space","IS\u002FOS (Ellipsoid Zone) Disruption","Retinal Pigment Epithelium (RPE) Elevation","Retinal Pigment Epithelium (RPE) Atrophy","RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2025-05-23",{"date":44,"type":20},"2026-08",{"name":46,"class":47},"Carl Zeiss Meditec-Dublin CoCe","INDUSTRY",6,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100604002","multi-modal-intelligent-diagnosis-system-for-multiple-ophthalmic-diseases-100604002","NCT07143851","Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases","Research on Key Technologies of Intelligent Auxiliary Diagnosis for Multiple Eye Diseases Based on Multimodal Ultra-High-Speed SS-OCT\u002FOCTA","Inclusion Criteria:\n\n* Diagnosed as macular degeneration, diabetic macular edema, retinal vein obstructive macular edema, high myopia, glaucoma or other clearly diagnosed ophthalmic diseases. The SS-OCT\u002FSS-OCTA images of the patient are clear.\n\nExclusion Criteria:\n\n* The image quality is poor and difficult to analyze due to reasons such as refractive media opacity and poor coordination.","20 Years","90 Years",{"count":59,"type":20},5000,"1 Day","OBSERVATIONAL","Aiming at the problems of low image reading efficiency, crowded medical resources and fragmented cross-modal information of ophthalmic OCT and OCTA, a multimodal large model diagnostic framework for various diseases such as retinal diseases and optic nerve damage in glaucoma is constructed to fully explore the complementary information of various images such as SS-OCT structural images, SS-OCTA vascular images and optic nerve scans. Extract cross-modal joint features to improve the accuracy of automatic diagnosis.",[29,64],"Glaucoma","NOT_YET_RECRUITING","2025-08-19",{"date":68,"type":40},"2025-08-27",{"date":70,"type":20},"2025-08-30",{"date":72,"type":20},"2028-06-30",{"name":74,"class":75},"Beijing Hospital","OTHER_GOV"]